Aloradine is a small molecule commercialized by VistaGen Therapeutics, with a leading Phase III program in Social Anxiety Disorder (SAD/Social Phobia). According to Globaldata, it is involved in 12 clinical trials, of which 8 were completed, 1 is ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Aloradine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Aloradine is expected to reach an annual total of $73 mn by 2032 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
fasedienol (PH-94B) is under development for the treatment of social anxiety disorders (social phobia), postpartum anxiety, post-traumatic stress disorder, pre-proceduralanxiety (pre-MRI) and adjustment disorder with anxiety related to the COVID-19 pandemic. It is a intranasally administered as neurosteroidal aerosol. PH-94B belongs to a family of pharmaceutical compounds called pherines. It was also under development for the treatment of generalized anxiety disorder.
VistaGen Therapeutics Overview
VistaGen Therapeutics (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate receptor glycine B intended to treat the major depressive disorder. Its other pipeline products comprise of PH94B treats social anxiety disorder and PH10 nasal spray treats for major depressive disorder. The company offers its products in the form of sprays and oral. It partners with other healthcare industries for researching and assessing drug effects on cardiac risk. VistaGen is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$1.1 million for the fiscal year ended March 2022 (FY2022), an increase of 1.8% over FY2021. The operating loss of the company was US$47.8 million in FY2022, compared to an operating loss of US$17.9 million in FY2021. The net loss of the company was US$47.8 million in FY2022, compared to a net loss of US$17.9 million in FY2021.
The company reported negative revenues of US$0.9 million for the second quarter ended September 2022, compared to a revenue of US$0.3 million the previous quarter.
For a complete picture of Aloradine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
#current #valuation #VistaGen #Therapeuticss #Aloradine